Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Medical Device

Shanghai HeartCare Medical Technology Receives NMPA Approval for Embolization Stent

Fineline Cube Nov 5, 2024

China’s National Medical Products Administration (NMPA) has granted marketing approval to Shanghai HeartCare Medical Technology...

Company Deals

Boehringer Ingelheim Partners with Broad Institute for Mental Health Treatments

Fineline Cube Nov 5, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a collaboration agreement with the Stanley Center...

Company Drug

HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment

Fineline Cube Nov 5, 2024

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food...

Company Medical Device

NMPA Grants Marketing License to Abonisi Medical Technology’s Knee Joint Prosthesis System

Fineline Cube Nov 5, 2024

China’s National Medical Products Administration (NMPA) has issued a marketing license to Abonisi Medical Technology...

Company Drug

Isap Biotech Secures FDA IND Approval for iSAP-0909 for Bladder Cancer Imaging

Fineline Cube Nov 5, 2024

Beijing-based biotech firm Isap Biotech has announced that it has received Investigational New Drug (IND)...

Company Drug

China Grand Pharmaceutical Completes Phase III Clinical Study for Post-Cataract Surgery Treatment

Fineline Cube Nov 5, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the successful completion...

Company Digital

111 Inc. Appoints Yang “Luke” Chen to Board of Directors Following Resignation of Dr. Lian Yong Chen

Fineline Cube Nov 5, 2024

China-based online pharmacy 111 Inc. (NASDAQ: YI) has announced the appointment of its Senior Finance...

Company Deals

Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan

Fineline Cube Nov 4, 2024

Chinese firms Shanghai RMX Biopharma Co. Ltd., a subsidiary of Haihe Biopharma Co., Ltd., and...

Policy / Regulatory

China’s National Allied Procurement Office Launches 10th VBP Tender Round Information Filing

Fineline Cube Nov 4, 2024

The National Allied Procurement Office has released a notification initiating the information filing process for...

Policy / Regulatory

NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status

Fineline Cube Nov 4, 2024

The National Medical Products Administration (NMPA) has released the 84th batch of reference drugs for...

Company Medical Device

J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment

Fineline Cube Nov 4, 2024

US major Johnson & Johnson (J&J, NYSE: JNJ) MedTech has announced the completion of pilot...

Company Drug

Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015

Fineline Cube Nov 4, 2024

Shenzhen-based Innorna Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD)...

Company Drug

Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial

Fineline Cube Nov 4, 2024

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has released new positive data on social functioning...

Company Deals

Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing

Fineline Cube Nov 4, 2024

Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful...

Company Medical Device

Suzhou Basecare Medical’s BKA210 Receives Marketing Approval in Jiangsu Province

Fineline Cube Nov 4, 2024

China-based in vitro fertilization (IVF) specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has announced...

Company Deals

Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital

Fineline Cube Nov 4, 2024

Hangzhou-based stem cell specialist Reprogenix has announced the successful completion of a Series A financing...

Company Drug

Novo Nordisk’s Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH

Fineline Cube Nov 4, 2024

Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO; CPH: Novo-B) has announced that part 1 of...

Company Drug

Jiuzhitang Co., Ltd Announces Clinical Clearance for Volagidemab in Type 1 Diabetes

Fineline Cube Nov 4, 2024

China-based traditional Chinese medicine (TCM) giant Jiuzhitang Co., Ltd (SHE: 000989) has announced that volagidemab...

Company Drug

Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study

Fineline Cube Nov 4, 2024

China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has received approval from the...

Company Deals

Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures

Fineline Cube Nov 4, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a...

Posts pagination

1 … 255 256 257 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.